以Hsp90为靶点治疗真菌感染的研究进展和展望

摘要/Abstract

摘要：

为了增强抗真菌药物的效能并避免真菌耐药,以分子伴侣Hsp90作为药物靶点是一个新的有前途的策略。对于系统性真菌感染,如果想要达到有效的联合用药效果,就需选择对病原真菌Hsp90有特异性作用的抑制剂。本文总结了Hsp90与病原真菌耐药的关系和对真菌毒力特征的调节,Hsp90功能的调节及其客户蛋白,并讨论了为治疗真菌感染而研发Hsp90抑制剂所面临的挑战。

关键词: 医学真菌, 抗真菌药物, 真菌耐药性, 热休克蛋白

Abstract:

A promising new strategy to enhance the efficacy of antifungal drugs and block the evolution of drug resistance is to target the molecular chaperone Hsp90.For systemic infections,however,effective combination therapy regimens may require Hsp90 inhibitors that can select target Hsp90 in the pathogen.In this review,we summarize studies of the impact of Hsp90 on drug resistance of fungal pathogens and regulation of key fungal virulence traits,regulator of Hsp90 function and the client proteins,and discuss the challenges for development of Hsp90 inhibitors to treat fungal infections.

Key words: fungus, antifungal agents, drug resistance, heat shock protein 90

中图分类号:

R978.5

杨苏腾, 廖勇, 巴根, 吕雪莲, 杨蓉娅. 以Hsp90为靶点治疗真菌感染的研究进展和展望[J]. 中国真菌学杂志, 2016, 11(1): 53-57.

YANG Su-teng, LIAO Yong, BA Gen, LV Xue-lian, YANG Rong-ya. Research progress on targeting Hsp90 for antifungal therapy[J]. Chinese Journal of Mycology, 2016, 11(1): 53-57.

参考文献

[1] Pfaller MA,Diekema DJ.Epidemiology of invasive mycoses in North America[J].Crit Rev Microbiol,2010,36(1):1-53.
[2] U.S.Deparment of Health and Human Services:Centers for Disease Control and Prevention.Antibiotic resistance threats in the United States,2013[R].Atlanta,USA:CDC,2013.
[3] Cowen LE,Steinbach WJ.Stress,drugs,and evolution:the role of cellular signaling in fungal drug resistance[J].Eukaryot Cell,2008,7(5):747-764.
[4] Cowen LE.The evolution of fungal drug resistance:modulating the trajectory from genotype to phenotype[J].Nat Rev Microbiol,2008,6(3):187-198.
[5] Leach MD,Klipp E,Cowen LE,et al.Fungal Hsp90:a biological transistor that tunes cellular outputs to thermal inputs[J].Nat Rev Microbiol,2012,10(10):693-704.
[6] Rutherford SL,Lindquist S.Hsp90 as a capacitor for morphological evolution[J].Nature,1998,396(6709):336-342.
[7] Sangster TA,Lindquist S,Queitsch C.Under cover:causes,effects and implications of Hsp90-mediated genetic capacitance[J].Bioessays,2004,26(4):348-362.
[8] Queitsch C,Sangster TA,Lindquist S.Hsp90 as a capacitor of phenotypic variation[J].Nature,2002,417(6889):618-624.
[9] Cowen LE,Lindquist S.Hsp90 potentiates the rapid evolution of new traits:drug resistance in diverse fungi[J].Science,2005,309(5744):2185-2189.
[10] Jarosz DF,Lindquist S.Hsp90 and environmental stress transform the adaptive value of natural genetic variation[J].Science,2010,330(6012):1820-1824.
[11] Miller LG,Hajjeh RA,Edwards JE Jr.Estimating the cost of nosocomial candidemia in the united states[J].Clin Infect Dis,2001,32(7):1110.
[12] Cowen LE.Hsp90 orchestrates stress response signaling governing fungal drug resistance[J].PLoS Pathog,2009,5(8):e1000471.
[13] Singh SD,Robbins N,Zaas AK,et al.Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin[J].PLoS Pathog,2009,5(7):e1000532.
[14] Singh-Babak SD,Babak T,Diezmann S,et al.Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata[J].PLoS Pathog,2012,8(5):e1002718.
[15] Lamoth F,Juvvadi PR,Gehrke C,et al.In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole-and echinocandin-resistant strains[J].Antimicrob Agents Chemother,2013,57(2):1035-1039.
[16] D'enfert C.Biofilms and their role in the resistance of pathogenic Candida to antifungal agents[J].Curr Drug Targets,2006,7(4):465-470.
[17] Robbins N,Uppuluri P,Nett J,et al.Hsp90 governs dispersion and drug resistance of fungal biofilms[J].PLoS Pathog,2011,7(9):e1002257.
[18] Diezmann S,Leach MD,Cowen LE.Functional Divergence of Hsp90 Genetic Interactions in Biofilm and Planktonic Cellular States[J].PLoS One,2015,10(9):e0137947.
[19] Noble SM,French S,Kohn LA,et al.Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity[J].Nat Genet,2010,42(7):590-598.
[20] Gow NA,Van De Veerdonk FL,Brown AJ,et al.Candida albicans morphogenesis and host defence:discriminating invasion from colonization[J].Nat Rev Microbiol,2012,10(2):112-122.
[21] Shapiro RS,Uppuluri P,Zaas AK,et al.Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling[J].Curr Biol,2009,19(8):621-629.
[22] Kovacs JJ,Murphy PJ,Gaillard S,et al.HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor[J].Mol Cell,2005,18(5):601-607.
[23] Scroggins BT,Robzyk K,Wang D,et al.An acetylation site in the middle domain of Hsp90 regulates chaperone function[J].Mol Cell,2007,25(1):151-159.
[24] Mollapour M,Tsutsumi S,Truman AW,et al.Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity[J].Mol Cell,2011,41(6):672-681.
[25] Diezmann S,Michaut M,Shapiro RS,et al.Mapping the Hsp90 genetic interaction network in Candida albicans reveals environmental contingency and rewired circuitry[J].PLoS Genet,2012,8(3):e1002562.
[26] Bruno VM,Mitchell AP.Regulation of azole drug susceptibility by Candida albicans protein kinase CK2[J].Mol Microbiol,2005,56(2):559-573.
[27] Robbins N,Leach MD,Cowen LE.Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance[J].Cell Rep,2012,2(4):878-888.
[28] Shapiro RS,Zaas AK,Betancourt-Quiroz M,et al.The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance[J].PLoS One,2012,7(9):e44734.
[29] Steinbach WJ,Cramer RA Jr,Perfect BZ,et al.Calcineurin controls growth,morphology,and pathogenicity in Aspergillus fumigatus[J].Eukaryot Cell,2006,5(7):1091-1103.
[30] Miyazaki T,Yamauchi S,Inamine T,et al.Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata[J].Antimicrob Agents Chemother,2010,54(4):1639-1643.
[31] Lafayette SL,Collins C,Zaas AK,et al.PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1,calcineurin,and Hsp90[J].PLoS Pathog,2010,6(8):e1001069.
[32] Millson SH,Truman AW,King V,et al.A two-hybrid screen of the yeast proteome for Hsp90 interactors uncovers a novel Hsp90 chaperone requirement in the activity of a stress-activated mitogen-activated protein kinase,Slt2p(Mpk1p)[J].Eukaryot Cell,2005,4(5):849-860.
[33] Gerik KJ,Donlin MJ,Soto CE,et al.Cell wall integrity is dependent on the PKC1 signal transduction pathway in Cryptococcus neoformans[J].Mol Microbiol,2005,58(2):393-408.
[34] Hodgetts S,Nooney L,Al-Akeel R,et al.Efungumab and caspofungin:pre-clinical data supporting synergy[J].J Antimicrob Chemother,2008,61(5):1132-1139.
[35] http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500017175.pdf.
[36] Louie A,Stein DS,Zack JZ,et al.Dose range evaluation of Mycograb C28Y variant,a human recombinant antibody fragment to heat shock protein 90,in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis[J].Antimicrob Agents Chemother,2011,55(7):3295-3304.
[37] Richie DL,Ghannoum MA,Isham N,et al.Nonspecific effect of Mycograb on amphotericin B MIC[J].Antimicrob Agents Chemother,2012,56(7):3963-3964.
[38] Cowen LE.The fungal Achilles' heel:targeting Hsp90 to cripple fungal pathogens[J].Curr Opin Microbiol,2013,16(4):377-384.
[39] Lamoth F,Alexander BD,Juvvadi PR,et al.Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species[J].J Antimicrob Chemother,2015,70(5):1408-1411.
[40] Southworth DR,Agard DA.Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle[J].Mol Cell,2008,32(5):631-640.